You are here: Home / Protocols / Pancreatic Cyst Biomarker Validation Study
Team Project

Pancreatic Cyst Biomarker Validation Study

Feng, ZidingFred Hutchinson Cancer Research Center
DNA Sequencing: KRAS , GNAS , VHL, CTNNB1, TP53, PIK3CA & PTEN (Aatur Singhi) DNA Methylation: SOX17, FOXE1, PTCHD2, SLIT2, EYA4 & SFRP1(Michael Goggins) Protein expression: MUC5AC:WGA, MUC5AC:BGH & endorepellin (Brian Haab) Amphiregulin expression & glucometer glucose (Walter Park) Protease activity: Gastricsin & Cathepsin E (Charles Craik) Protein expression: Das-1 (Koushik Das) Protein activity: Telomerase (Michael Goggins)
G.I. and Other Associated Cancers Research Group

With the rapid utilization and ongoing advancements in cross-sectional abdominal imaging, the detection of pancreatic cysts has become increasingly frequent. It is reported pancreatic cysts are identified in 1.2- 2.6% of abdominal computed tomography (CT) scans. Many of these cysts, including serous cystadenomas (SCA) and pseudocysts, are benign and can be monitored clinically. In contrast, mucinous cysts, which include intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), have the potential to progress to pancreatic adenocarcinoma (PDAC). Currently, a multidisciplinary approach is recommended in the assessment of pancreatic cysts. This includes clinical and radiographic evaluation, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), cytology, cyst fluid analysis (e.g., viscosity) and tumor markers (e.g., carcinoembryonic antigen (CEA)). Despite a combination of methodologies, the distinction between mucinous cysts from other pancreatic cysts can be difficult. Moreover, the detection of PDAC within a pancreatic cyst can be even more challenging. Thus, there is a dire need for diagnostic tests that can accurately differentiate mucinous from non-mucinous pancreatic cysts and the presence versus absence of advanced neoplasia within a pancreatic cyst. This proposal represents the formation of a multiinstitutional team investigators under the collective name of the Pancreatic Cyst Biomarker Alliance (PCBA) and will validate seven promising pancreatic cyst fluid biomarkers. These biomarkers include targeted DNA somatic and epigenetic alterations, elevations in protein expression, increased protein enzymatic activity and decreasing metabolites that can be easily assayed using minimal amounts of aspirated pancreatic cyst fluid. Within a two-year timeframe, the PCBA will blindly evaluate over 200 pancreatic cyst specimens per assay to establish their future clinical utility. Moreover, these biomarkers will be correlated with known clinicopathologic variables relevant to pancreatic cysts and cross-validated with other assays. Upon completion of this study, the PCBA will have identified and optimized pancreatic cyst fluid biomarkers for future prospective clinical trials.

Create a Pancreatic Cyst Biomarker Alliance (PCBA) reference set to validate seven pancreatic cyst fluid biomarkers that have shown considerable promise to changing standard clinical practice for pancreatic cysts.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

🔜 Data-Sci Workshop
The EDRN Biomarker Data Science Workshop is coming this August, 2020. More details available soon.
Announcement 03/17/2020

The EDRN Registration page will be available soon to register for the 35th EDRN Steering Committee Meeting, now scheduled to take place from June 30-July 2, 2020, in Tempe, AZ.

This icon signifies that something is happening and we kindly ask you to please wait